about
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumoursFirst-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsSelective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Serum tumor markers in bile duct cancer--a review.Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.Three-year follow-up of implementation of evidence-based transfusion practice in a tertiary hospital.Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.Detection of copy number alterations in cell-free tumor DNA from plasma.Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia.The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy.Patient information in phase 1 trials: A systematic review.A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.Copenhagen Prospective Personalized Oncology (CoPPO) - Clinical utility of using molecular profiling to select patients to phase 1 trialsTOP1 gene copy numbers are increased in cancers of the bile duct and pancreasEnhanced detection of circulating tumor DNA by fragment size analysisCirculating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsPrognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patientsApplication of cell-free DNA for genomic tumor profiling: a feasibility studyA phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancersTisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialHigh frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancerEfficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast CancerSocioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control StudyA phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentPlasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
P50
Q33377549-C87A647D-C8AD-44D2-BF2B-613813F56060Q33380564-2C031571-9FED-4E60-BC2D-FDE3FAA6C1B1Q33390447-00826175-AF6E-4B9A-9065-E43F9A593965Q33430367-CA8B3897-484E-4585-B24B-48F703A49146Q33441578-0B628C15-012D-4D73-B8A1-AA1E36E985FEQ34132872-F8D0595C-5E70-4E56-AB98-F84741ABEADEQ38214343-D8CDABBD-35AF-46B1-B7A4-D2D6ECCA318EQ38386529-070EFD3A-A497-4A84-B3F4-C7AFB8891669Q38881093-5B21EFA3-F866-4A03-809D-8F26125E4563Q38948699-50E1160D-6BFB-4C38-80EC-E75DB1511CE6Q38950876-06A4341B-55C0-45AA-9D6D-E1DB671FBDB8Q40661166-510018DA-24CC-4782-88D2-5D93BCA2E293Q40942753-779BB026-F5AF-40FB-B10D-CF6415BF2804Q42291714-5C6B50FE-601C-4468-A04E-E3EB068A4BD7Q42642023-871860B5-C9CF-48BE-9039-C0EB717D3922Q46793337-EED750A1-4518-4D3D-AC4F-E32FB837BB8CQ47332491-0DC42B42-4FB2-4D1D-B381-93CAF3A3CA0BQ47424261-0B07CA84-DDCE-4F00-9F60-04C676AE94F8Q47715010-F922BE8C-BC85-4685-A53A-9167A63E6A4DQ48270408-ED109A90-EC9B-428C-B607-ABBB98E02FCBQ49157409-F6EAA251-461F-4695-BD0B-077583235793Q50073413-E018BC72-9E83-42CF-8D2B-DBE0B217E7E6Q51288413-8E1EFAA8-4102-4A9D-A9C8-5668869E6967Q53323640-0CC13635-3A4E-4C64-A1A5-7822F836C493Q53564949-81DB668A-0423-479A-AB8E-379A755B0872Q54612028-A8BEEB50-8847-410B-AE7A-48CF3BAD17F3Q57053756-FE82887B-2C20-4035-B216-881A2EAD8583Q57146053-49615777-C4C6-4F6B-83B5-8A7BB306A4FDQ58602903-7C7F9EB7-A846-492E-863E-755542BAA605Q58704645-74963F7D-B652-4AB9-8EE4-1CA8A01AF733Q64110648-EBB62644-D63D-4159-A6CB-39C9B4A2BA95Q64240220-1FCA7943-DE19-4694-90C3-7335910B697AQ85944296-A76290F8-B444-497B-86EF-6DC44A717B1EQ91465884-2EC77227-56BE-4A7E-BB37-BD0F88249F52Q91533135-D791B8A4-8243-4BF0-8A8D-E09A22518C87Q91733989-B447D6D7-338E-46AB-94FF-B7B45146D704Q92298884-629B6CDF-DEE0-498D-9EC1-C4B5D7AB8F95Q92378452-41F98702-52DC-4A19-AD67-8821D5E14D96Q92405534-35DF81A3-D03D-4C83-A957-79D2622369E8Q92667785-477BAB1F-57C8-4DA7-AA68-ABC1A7ACD019
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Morten Mau-Sorensen
@ast
Morten Mau-Sorensen
@en
Morten Mau-Sorensen
@es
Morten Mau-Sorensen
@nl
Morten Mau-Sorensen
@sl
type
label
Morten Mau-Sorensen
@ast
Morten Mau-Sorensen
@en
Morten Mau-Sorensen
@es
Morten Mau-Sorensen
@nl
Morten Mau-Sorensen
@sl
altLabel
Morten Mau-Soerensen
@en
Morten Mau-Sorensen
@en
Paul Morten Mau-Sørensen
@en
prefLabel
Morten Mau-Sorensen
@ast
Morten Mau-Sorensen
@en
Morten Mau-Sorensen
@es
Morten Mau-Sorensen
@nl
Morten Mau-Sorensen
@sl
P106
P1153
55798653200
P21
P214
109147905208179091312
P31
P496
0000-0003-2235-1250
P735
P7859
viaf-109147905208179091312